Fenofibrate is a Medicine belongs to Cardiovascular drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 1416   Edition : 37  

  ►   Brandname : Fenolip, Lipicard, Fenogal, Lipantil, Antara, Lipofen
  ►  Strength : Tablet with 48 mg.  Tablet with 50 mg.  Tablet with 54 mg.  Tablet with 107 mg.  Tablet with 145 mg.  Tablet with 160 mg.  Capsule with 45 mg.  Capsule with 50 mg.  Capsule with 67 mg.  Capsule with 100 mg.  Capsule with 130 mg.  Capsule with 134 mg.  Capsule with 135 mg.  Capsule with 150 mg.  Capsule with 200 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 633   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 1416   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Hyperlipidaemias Oral 67 mg Capsule t.i.d. (These are Standard micronised formulations) or given as 200 mg once daily; the dose may be reduced to 67 mg twice daily or increased to 67 mg four times daily or 267 mg once daily according to response.

Ref :-  Book : Martindale    Page : 1381   Edition : 38  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Hyperlipidaemias 4 Year 15 Year Oral 67 mg Capsule

Ref :- Book : Martindale    Page : 1381   Edition : 38  
►  Side Effect : Dyspepsia, Myalgia, Gallstones, Xerostomia, Myopathy when coadministered with a statin, Elevation of liver-function test values, Arrhythmias
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 331   Edition : 3.      Page :    Edition : .  

►  Drug Interaction : Drug interaction of Fenofibrate is with Oral anticoagulants, , Statins, ,  Warfarin , Tolbutamide , Phenytoin , Furosemide , Cyclosporine
Ref :-   Book : Martindale    Page : 1357   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Bezafibrate and other fibrates are highly protein-bound and may displace other drugs from protein binding sites. Interactions may also occur through changes in the activity of cytochrome P450 isoenzymes, particularly CYP3A4. Fibrates may enhance the effects of oral anticoagulants; the dose of anticoagulant should be reduced involved. Recommendations vary; licensed product information for bezafibrate suggests a reduction of up to 50% in the dosage of anticoagulant. The mechanism of the interaction is unclear; fibrates have been reported to displace warfarin from protein binding sites but other mechanisms are probably also involved. Other drugs that may be displaced from plasma proteins by fibrates include tolbutamide and other sulfonylurea antidiabetics, phenytoin, and, in patients with hypoalbuminaemia, furosemide. The interaction with antidiabetics is complex since fibrates may alter glucose tolerance in diabetic patients.The dosage of antidiabetics may need adjusting during bezafibrate therapy. There is an increased risk of myopathy if fibrates are used with statins. Fibrates may interact with ciclosporin, although reports have been conflicting nephrotoxicity associated with increased ciclosporin concentrations has been reported with bezafibrate and renal function should be monitored. Cholestasis has been reported in a patient given fenofibrate with raloxifene.
Ref :-   Book : Martindale    Page : 1357   Edition : 37.  

►  Contraindication : Pre-existing gallbladder disease, Severe renal impairment, Hepatic dysfunction
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 331   Edition : 3.  
  ►  Mechanism of Action :   Fibrates function primarily as ligands for the nuclear transcription receptor, PPAR-α. They transcriptionally up-regulate LPL, apo A-I and apo A-II, and down-regulate apo C-III, an inhibitor of lipolysis. A major effect is an increase in oxidation of fatty acids in liver and striated muscle. They increase lipolysis of lipoprotein triglyceride via LPL. Intracellular lipolysis in adipose tissue is decreased. Levels of VLDL decrease, in part as a result of decreased secretion by the liver. Only modest reductions of LDL occur in most patients. In others, especially those with combined hyperlipidemia, LDL often increases as triglycerides are reduced. HDL cholesterol increases moderately.
Ref :-   Book : Basic & Clinical pharmacology    Page : 628,629   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- VITAMIN B12 with Reduces vitamin & mineral absorption ..   BETACAROTENE with Reduces vitamin & mineral absorption ..   IRON with Reduces vitamin & mineral absorption ..  

  ►  Reference :-
  • Michael, Z. (2007). Hand book of nutrition. New York: Thieme Stuttgart

  •   ►  URL --

    ►   Route of Elimination :   Renal
    Ref :-   Book : Martindale    Page : 1415   Edition : 37.  

    ►    Plasma Half-life :   Min value :-   20 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 1415   Edition : 37.  

    ►    Peak Plasma Concentration :   Min value :-   nf,    Max value :-   NA
    Ref :-   Book :    Page :    Edition : .